Stem cell-based therapies in inflammatory bowel disease: Promises and pitfalls

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 4, 2016, Pages 533-547

  Duran, Natalie E ^a   Hommes, Daniel W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; hematopoietic stem cells; inflammatory bowel disease; mesenchymal stem cells; stem cell therapy

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOPTIVE TRANSFER; CELL DIFFERENTIATION; CHRONIC GRAFT VERSUS HOST DISEASE; CROHN DISEASE; ENGRAFTMENT; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INDUCED PLURIPOTENT STEM CELL; INFLAMMATORY BOWEL DISEASE; LEUKAPHERESIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; ULCERATIVE COLITIS;

EID: 84975029002     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16642190     Document Type: Review

References (125)

1. Anderson C., Boucher G, Lees C., Franke A., D'Amato M., Taylor K., et al. (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43: 246-252.
2. Ankrum J., Ong J., Karp J., (2014) Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotech 32: 252-260.
3. Augello A., Tasso R., Negrini S., Amateis A., Indiveri F., Cancedda R., et al. (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35: 1482-1490.
4. Baron F., Hermanne J., Dowlati A., Weber T., Thiry A., Fassotte M., et al. (1998) Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. Bone Marrow Transpl 21: 951-954.
5. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., Mcintosh K., Patil S., et al. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30: 42-48.
6. Baumgart D., Sandborn W., (2012) Crohn's disease. Lancet 380: 1590-1605.
7. Beaugerie L., Itzkowitz S.H., (2015) Cancers complicating inflammatory bowel disease. New England J Med 372: 1441-1452.
8. Bekkum D., (2000) Immune ablation and stem-cell therapy in autoimmune disease. Experimental basis for autologous stem-cell transplantation. Arthritis Res 2: 281-284.
9. Bernardo M., Zaffaroni N., Novara F., Cometa A., Avanzini M., Moretta A., et al. (2007) Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67: 9142-9149.
10. Bielefeldt K., Davis B., Binion D., (2009) Pain and inflammatory bowel disease. Inflamm Bowel Dis 15: 778-788.
11. Bierman P., Sweetenham J., Loberiza F., Taghipour G., Lazarus H., Rizzo J., et al. (2003) Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-the lymphoma working committee of the international bone marrow transplant registry and the European group for blood and marrow transplantation. J Clin Oncol 21: 3744-3753.
12. Bjorkman P., Saper M., Samraoui B., Bennett W., Strominger J., Wiley D., (1987) Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329: 506-512.
13. Brandenberger R., (2011) Cell therapy bioprocessing. BioProcess Int 30-37.
14. Broberger O., Perlmann P., (1959) Autoantibodies in human ulcerative colitis. J Exp Med 110: 657-674.
15. Burt R., Burns W., Hess A., (1995) Bone marrow transplantation for multiple sclerosis. Bone Marrow Transpl 16: 1-6.
16. Burt R., Craig R., Milanetti F., Quigley K., Gozdziak P., Bucha J., et al. (2010) Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn's disease: long-term follow up. Blood 116: 6123-6132.
17. Cassinotti A., Annaloro C., Ardizzone S., Onida F., Della Volpe A., Clerici M., et al. (2008) Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 57: 211-217.
18. Cassinotti A., Onida F., Annaloro C., Sampietro G., Fociani P., Fichera M., et al. (2012) P362 autologous haematopoietic stem cell transplantation without cd34+ cell selection for refractory Crohn's disease: the Milan experience after 5 years. J Crohns Colitis 6: S153-S154.
19. Castro J., Benich H., Smith L., Kalter S., Bachier C., Meneghetti C., et al. (1996) Prolonged clinical remission in patients with inflammatory bowel disease (IBD) after high dose chemotherapy (HDC) and autologous blood stem cell transplantation. Blood 88: 133A.
20. Chassaing B., Darfeuille-Michaud A., (2011) The Commensal Microbiota and Enteropathogens in the Pathogenesis of Inflammatory Bowel Diseases. Gastroenterology 140: 1720-1728.
21. Ciccocioppo R., Bernardo M., Sgarella A., Maccario R., Avanzini M., Ubezio C., et al. (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60: 788-798.
22. Clerici M., Cassinotti A., Onida F., Trabattoni D., Annaloro C., Della Volpe A., et al. (2011) Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis 43: 946-952.
23. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A., (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140: 1785-1794.
24. Da Silva Meirelles L., Chagastelles P., Nardi N., (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119: 2204-2213.
25. Daikeler T., Hugle T., Farge D., Andolina M., Gualandi F., Baldomero H., et al. (2009) allogeneic hematopoietic sct for patients with autoimmune diseases. Bone Marrow Transpl 44: 27-33.
26. Das K., Biancone L., (2008) Is IBD an autoimmune disorder? Inflamm Bowel Dis 14: S97-S101.
27. De La Portilla F., Alba F., Garcia-Olmo D., Herrerias J., Gonzalez F., Galindo A., (2013) Expanded allogeneic adipose-derived stem cells (eascs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28: 313-323.
28. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P., Matteucci P., et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843.
29. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
30. Drakos P., Nagler A., Or R., (1993) Case of Crohn's disease in bone marrow transplantation. Am J Hematol 43: 157-158.
31. Duerr R., Targan S., Landers C., Larusso N., Lindsay K., Wiesner R., et al. (1991) Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 100: 1385-1391.
32. Duijvestein M., Molendijk I., Roelofs H., Vos A., Verhaar A., Reinders M., et al. (2011) Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. Cytotherapy 13: 1066-1073.
33. Duijvestein M., Vos A., Roelofs H., Wildenberg M., Wendrich B., Verspaget H., et al. (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59: 1662-1669.
34. Ebert E., Geng X., Bajpai M., Pan Z., Tatar E., Das K., (2009) Antibody to tropomyosin isoform 5 and complement induce the lysis of colonocytes in ulcerative colitis. Am J Gastroenterology 104: 2996-3003.
35. Farge D., Labopin M., Tyndall A., Fassas A., Mancardi G., Van Laar J., et al. (2010) Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European group for blood and marrow transplantation working party on autoimmune diseases. Haematologica 95: 284-292.
36. Fiocchi C., (2012) Genes and 'in-vironment': how will our concepts on the pathophysiology of inflammatory bowel disease develop in the future? Dig Dis 30: 2-11.
37. Forbes G., Sturm M., Leong R., Sparrow M., Segarajasingam D., Cummins A., et al. (2014) A phase II study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12: 64-71.
38. Franke A., Balschun T., Karlsen T., Sventoraityte J., Nikolaus S., Mayr G., et al. (2008) Sequence variants in il10, arpc2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40: 1319-1323.
39. Franke A., McGovern D., Barrett J., Wang K., Radford-Smith G., Ahmad T., et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42: 1118-1125.
40. Friedenstein A., Chailakhyan R., Latsinik N., Panasyuk A., Keiliss-Borok I., (1974) Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17: 331-340.
41. Gazouli M., Roubelakis M., Theodoropoulos G., (2014) Stem cells as potential targeted therapy for inflammatory bowel disease. Inflamm Bowel Dis 20: 952-955.
42. Geng X., Liu J., Lin J., Taniguchi M., Kosa E., Glazier K., et al. (2001) Autoimmunity against human tropomyosin isoform 5 (HTM5) in ulcerative colitis: antigen specific T cell response against the c terminal domain of HTM5. Gastroenterology 120: A520-A521.
43. Ghosh S., Mitchell R., (2007) Impact of inflammatory bowel disease on quality of life: results of the European federation of Crohn's and ulcerative colitis associations (EFCCA) patient survey. J Crohns Colitis 1: 10-20.
44. Gratwohl A., Passweg J., Bocelli-Tyndall C., Fassas A., Van Laar J., Farge D., et al. (2005) Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transpl 35: 869-879.
45. Gurdon J., (1962) The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 10: 622-640.
46. Hanauer S., Feagan B., Lichtenstein G., Mayer L., Schreiber S., Colombel J., et al. (2002) Maintenance infliximab for Crohn's disease: the Accent I randomised trial. Lancet 359: 1541-1549.
47. Haque R., Lei F., Xiong X., Bian Y., Zhao B., Wu Y., et al. (2012) Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J Immunol 189: 1228-1236.
48. Hasselblatt P., Drognitz K., Potthoff K., Bertz H., Kruis W., Schmidt C., et al. (2012) Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther 36: 725-735.
49. Hawkey C., (2014) OC-007 haemopoetic stem cell transplantation for severe resistant Crohn's disease: preliminary evidence for durable benefit. Gut 63: A4.
50. Hawkey C., Allez M., Clark M., Labopin M., Lindsay J., Ricart E., et al. (2015) Autologous hematopoetic stem cell transplantation for refractory crohn disease: a randomized clinical trial. JAMA 314: 2524-2534.
51. Hellers G., Bergstrand O., Ewerth S., Holmstrom B., (1980) Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 21: 525-527.
52. Hendrickson B., Gokhale R., Cho J., (2002) Clinical aspects and pathophysiology of inflammatory bowel disease. Clinical Microbiology Reviews 15: 79-94.
53. Heslop J., Hammond T., Santeramo I., Tort Piella A., Hopp I., Zhou J., et al. (2015) Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med 4: 389-400.
54. Hommes D., Colombel J., Emery P., Greco M., Sandborn W., (2012) Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis 6: S224-S234.
55. Hommes D., Lacey P., (2016) Stem cells: HSCT for Crohn's disease: work in progress or a bridge too far? Nat Rev Gastroenterol Hepatol 13: 128-130.
56. Hwang J., Varma M., (2008) Surgery for inflammatory bowel disease. World J Gastroenterol 14: 2678-2690.
57. Ikehara S., (2001) Treatment of autoimmune diseases by hematopoietic stem cell transplantation. Exp Hematol 29: 661-669.
58. Iwasaki T., (2004) Recent advances in the treatment of graft-versus-host disease. Clin Med Res 2: 243-252.
59. Jacobs P., Vincent M., Martell R., (1986) Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia. Bone Marrow Transpl 1: 237-239.
60. Janeway C., Travers P., Walport M., Shlomchik M., (2001) Immunobiology: The Immune System In Health And Disease, 5th edition. Garland Science: New York.
61. Jauregui-Amezaga A., Rovira M., Pinó Donnay S., Marín P., Feu F., Elizalde J., et al. (2014) P471 hematopoietic stem cell transplantation in refractory Crohn's disease: feasibility and toxicity. J Crohns Colitis 8: S263-S263.
62. Kashyap A., (1998) Autologous bone marrow transplantation for non-hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. Brit J Haematol 103: 651-652.
63. Kavanagh D., Kalia N., (2011) Hematopoietic stem cell homing to injured tissues. Stem Cell Rev 7: 672-682.
64. Knoepfler P., (2009) Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells (Dayton, Ohio) 27: 1050-1056.
65. Korsmeyer S., Williams R., Wilson I., Strickland R., (1975) Lymphocytotoxic antibody in inflammatory bowel disease: a family study. New England J Med 293: 1117-1120.
66. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. (2003) Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722-3729.
67. Lanzoni G., Roda G., Belluzzi A., Roda E., Bagnara G., (2008) Inflammatory bowel disease: moving toward a stem cell-based therapy. World J Gastroenterol 14: 4616-4626.
68. Larocca A., Piaggio G., Podesta M., Pitto A., Bruno B., Di Grazia C., et al. (2006) Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91: 935-940.
69. Lazebnik L., Knyazev O., Parfenov A., Ruchkina I., Shcherbakov P., Khomeriki S., et al. (2012a) Optimization of cell therapy in patients with inflammatory bowel diseases. Ter Arkh 84: 10-17.
70. Lazebnik L., Lychkova A., Knyazev O., (2012b) Treatment of experimental ulcerative colitis. Bull Exp Biol Med 153: 889-892.
71. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O., (2003a) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31: 890-896.
72. Le Blanc K., Tammik L., Sundberg B., Haynesworth S., Ringden O., (2003b) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57: 11-20.
73. Lee S., Vogelsang G., Flowers M., (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transpl 9: 215-233.
74. Lee W., Park K., Cho Y., Yoon S., Song K., Kim Do S., et al. (2013) Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells 31: 2575-2581.
75. Lehmann W., (2014) Athersys announces results from phase II study of multistem(r) cell therapy for ulcerative colitis; multistem demonstrates good tolerability and safety profile but fails to show efficacy over 8 weeks in patients with chronic, advanced ulcerative colitis. Press release Athersys Inc. Available at: Athersys.com.
76. Liang J., Zhang H., Wang D., Feng X., Wang H., Hua B., et al. (2012) Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut 61: 468-469.
77. Lopez-Cubero S., Sullivan K., McDonald G., (1998) Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 114: 422-440.
78. Lowenthal R., Cohen M., Atkinson K., Biggs J., (1993) Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 20: 137-140.
79. Macias M., Grande J., Moreno A., Dominguez I., Bornstein R., Flores A., (2010) Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers. Am J Obstet Gynecol 203: 495, e499, e423.
80. Marti J., Mayordomo J., Isla M., Saenz A., Escudero P., Tres A., (2001) PBSC autotransplant for inflammatory bowel disease (IBD): a case of ulcerative colitis. Bone Marrow Transpl 28: 109-110.
81. Martinez-Montiel Mdel P., Gomez-Gomez G., Flores A., (2014) Therapy with stem cells in inflammatory bowel disease. World J Gastroenterol 20: 1211-1227.
82. Meldrum J., (2014) Mesoblast provides update on clinical programs of prochymal for Crohn's disease and acute graft versus host disease. Mesoblast Ltd. Press release 28 2014. Available at: mesoblast.com.
83. Melief S., Schrama E., Brugman M., Tiemessen M., Hoogduijn M., Fibbe W., et al. (2013) Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31: 1980-1991.
84. Mitchell A., Guyatt G., Singer J., Irvine E., Goodacre R., Tompkins C., et al. (1988) Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 10: 306-310.
85. Molendijk I., Bonsing B., Roelofs H., Peeters K., Wasser M., Dijkstra G., et al. (2015) Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology 149: 918-27, e6.
86. Molendijk I., Nuij V., Van Der Meulen-De Jong A., Van Der Woude C., (2014) Disappointing durable remission rates in complex Crohn's disease fistula. Inflamm Bowel Dis 20: 2022-2028.
87. Molodecky N., Soon I., Rabi D., Ghali W., Ferris M., Chernoff G., et al. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142: 46-54 e42, quiz e30.
88. Nauta A., Westerhuis G., Kruisselbrink A., Lurvink E., Willemze R., Fibbe W., (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120.
89. Onken J., Gallup D., Hanson J., Pandak M., Custer L., (2006) Successful outpatient treatment of refractory Crohn's disease using adult mesenchymal stem cells. American College of Gastroenterology Conference: Abstract 121.
90. Ordas I., Eckmann L., Talamini M., Baumgart D., Sandborn W., (2012) Ulcerative colitis. Lancet 380: 1606-1619.
91. Oyama Y., Craig R., Traynor A., Quigley K., Statkute L., Halverson A., et al. (2005) Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128: 552-563.
92. Pasquini M., Zhu X., (2015) Current use and outcome of hematopoietic stem cell transplantation: 2014 CIBMTR summary slides. Available at: http://www.cibmtr.org.
93. Peyrin-Biroulet L., Lemann M., (2011) Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 33: 870-879.
94. Pittenger M., Mackay A., Beck S., Jaiswal R., Douglas R., Mosca J., et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
95. Raina P., (2007) Evaluation of Prochymal® adult human stem cells for treatment-resistant moderate-to-severe Crohn's disease. ClinicalTrials.gov identifier: NCT00482092.
96. Ramirez R., Fleshner P., (2006) Reoperative inflammatory bowel disease surgery. Clin Colon Rectal Surg 19: 195-206.
97. Rattue P., (2012) Prochymal-first stem cell drug approved. Medical News Today 22 2012.
98. Reya T., Morrison S., Clarke M., Weissman I., (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
99. Rogler G., Vavricka S., Schoepfer A., Lakatos P., (2013) Mucosal healing and deep remission: what does it mean? World J Gastroenterol 19: 7552-7560.
100. Sallerfors B., Olofsson T., (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by adherent monocytes measured by quantitative immunoassays. Eur J Haematol 49: 199-207.
101. Satterthwaite A., Burn T., Le Beau M., Tenen D., (1992) Structure of the gene encoding CD34, a human hematopoietic stem cell antigen. Genomics 12: 788-794.
102. Scalapino K., Daikh D., (2009) Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells. PLoS One 4: e6031.
103. Scharl M., Rogler G., (2012) Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterology 28: 301-309.
104. Schu S., Nosov M., O'Flynn L., Shaw G., Treacy O., Barry F., et al. (2012) Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 16: 2094-2103.
105. Schwartz D., Loftus E., Tremaine W., Panaccione R., Harmsen W., Zinsmeister A., et al. (2002) The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 122: 875-880.
106. Sensebe L., Krampera M., Schrezenmeier H., Bourin P., Giordano R., (2010) Mesenchymal stem cells for clinical application. Vox Sang 98: 93-107.
107. Shah N., Kammermeier J., Elawad M., Glocker E., (2012) Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep 12: 373-379.
108. Simmons D., Satterthwaite A., Tenen D., Seed B., (1992) Molecular cloning of a CDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol 148: 267-271.
109. Smith B., Tang K., Nutbeam D., (2006) WHO health promotion glossary: new terms. Health Promot Int 21: 340-345.
110. Sonwalkar S., James R., Ahmad T., Zhang L., Verbeke C., Barnard D., et al. (2003) Fulminant Crohn's colitis after allogeneic stem cell transplantation. Gut 52: 1518-1521.
111. Spence J., Mayhew C., Rankin S., Kuhar M., Vallance J., Tolle K., et al. (2011) Directed Differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470: 105-109.
112. Spiers A., (1984) Ulcerative colitis after bone-marrow transplantation for acute leukemia. N Engl J Med 311: 1259.
113. Stappenbeck T., Miyoshi H., (2009) The role of stromal stem cells in tissue regeneration and wound repair. Science 324: 1666-1669.
114. Swenson E., Theise N., (2010) Stem cell therapeutics: potential in the treatment of inflammatory bowel disease. Clin Exp Gastroenterol 3: 1-10.
115. Takahashi K., Yamanaka S., (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
116. Tarte K., Gaillard J., Lataillade J., Fouillard L., Becker M., Mossafa H., et al. (2010) Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115: 1549-1553.
117. Thomas A., Lodhia N., (2014) Advanced therapy for inflammatory bowel disease: a guide for the primary care physician. J Am Board Fam Med 27: 411-420.
118. Van Bekkum D., (2000) Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol 20: 10-16.
119. Van Deen W., (2012) Hematopoietic Stem Cells: New Research. Montgomery W., Burton H., (eds). Nova Science Publishers.
120. Vester-Andersen M., Prosberg M., Jess T., Andersson M., Bengtsson B., Blixt T., et al. (2014) Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 109: 705-714.
121. Wen Z., Fiocchi C., (2004) Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 11: 195-204.
122. Wright G., Notley C., Xue S., Bendle G., Holler A., Schumacher T., et al. (2009) Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Nat Acad Sci USA 106: 19078-19083.
123. Yin J., Jowitt S., (1992) Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transpl 9: 31-33.
124. Zand A., Van Deen W., Inserra E., Hall L., Kane E., Centeno A., et al. (2015) Presenteeism in inflammatory bowel diseases: a hidden problem with significant economic impact. Inflamm Bowel Dis 21: 1623-1630.
125. Zuk P., Zhu M., Ashjian P., De Ugarte D., Huang J., Mizuno H., et al. (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13: 4279-4295.